Company profile
KAMADA LTD
NASDAQ:KMDABiotechnology: Pharmaceutical Preparations
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01217671 | phase2_3 | completed | 2009-12-01 | 2014-11-01 | Kamada, Ltd. | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema |
| NCT00499837 | phase2 | completed | 2007-09-01 | 2008-07-01 | Kamada, Ltd. | Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients |
| NCT02005848 | phase2 | completed | 2014-04-01 | 2017-02-01 | Kamada, Ltd. | Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes |
| NCT02001688 | phase2 | completed | 2014-04-01 | 2016-02-01 | Kamada, Ltd. | Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" |
| NCT00460096 | phase2_3 | completed | 2007-03-01 | — | Kamada, Ltd. | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency |
FDA applications (5)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103189 | BLA | Kamada Ltd. | ||||
Loading… | ||||||
| BLA 103649 | BLA | Kamada Ltd. | ||||
Loading… | ||||||
| BLA 125035 | BLA | Kamada Ltd. | ||||
Loading… | ||||||
| BLA 125430 | BLA | Kamada Ltd. | ||||
Loading… | ||||||
| BLA 125613 | BLA | Kamada Ltd. | ||||
Loading… | ||||||